<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-rchp-1l-dlbcl-kuwait-hamed">
    <meta name="study:title" content="PB3294 - Pola-R-CHP in 1st line treatment DLBCL. Kuwait Cancer Center experience">
    <meta name="study:fileName" content="Abstracts/POLA-RCHP-1L-DLBCL-KUWAIT-HAMED.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence"> <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Prednisone,Chemotherapy,CIT,Pola-R-CHP">

    <title>PB3294: Pola-R-CHP in 1L DLBCL (Kuwait Experience) (Hamed) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3294 - Pola-R-CHP in 1L DLBCL (Kuwait Cancer Center Experience)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=25 Enrolled, 20 Evaluable)</h4>
                    <p>Newly diagnosed DLBCL (Kuwait). Aim: Compare real-world Pola-R-CHP to POLARIX trial.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pola-R-CHP)</h4>
                    <p>Pola-R-CHP (Polarix regimen) as first-line therapy. Retrospective data from KCCC.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=20 Evaluable)</h4>
                    <p>EOT PET CRR: <span class="highlight-value">75%</span> (vs 78% POLARIX)<br>1-yr OS: 94.4%, 1-yr PFS: 88.9%</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Comparable outcomes to POLARIX despite worse prognostics. Effective in real-world. Longer F/U needed.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3294 - Pola-R-CHP in 1st line treatment DLBCL. Kuwait Cancer Center experience</h1>
            <p class="abstract-sub-header">Rasha Abd El-Tawab Hamed, Salem Alshemmari, Abdulaziz Hamadah, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3294 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>DLBCL: ~30% of NHL, most common aggressive lymphoma.</li>
                        <li>Incidence increases with age (most diagnosed 65-74 yrs).</li>
                        <li>~40% relapse or are refractory to 1L R-CHOP. Median survival 6 mo if untreated.</li>
                        <li>Pola-R-CHP is an approved 1L treatment option.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To compare response to Pola-R-CHP (Polarix regimen) and 1-year PFS in newly diagnosed DLBCL patients at Kuwait Cancer Control Center (KCCC) with the original POLARIX trial.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective data from KCCC. Patients treated since March 2023.</li>
                        <li>N=25 patients received Polarix regimen; 5 still on treatment.</li>
                        <li>Efficacy data presented for N=20 evaluable patients.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Real-World Study Overview (KCCC)</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=25 Enrolled, N=20 Evaluable)</strong>
                            <span>Newly Diagnosed DLBCL at KCCC (since Mar 2023)</span>
                        </div>
                        <div class="schema-arrow-down">‚ñº</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Treatment Received</strong>
                                <span>Pola-R-CHP (Polarix Regimen)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Response (PET CRR at EOT)</span>
                           <span>1-Year PFS & OS</span>
                           <span>Comparison to POLARIX Trial Data</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (KCCC Cohort, N=25 unless stated)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>KCCC Cohort (N=25)</th><th>POLARIX Trial (N=440)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>62 (24-76)</td><td>65 (19-80)</td></tr>
                                <tr><td>Age >60 years, n (%)</td><td>14 (56.0%)</td><td>300 (68.2%)</td></tr>
                                <tr><td>Male, n (%)</td><td>14 (56.0%)</td><td>239 (54.3%)</td></tr>
                                <tr><td>ECOG PS 0-1, n (%)</td><td>12 (48.0%)</td><td>374 (85.0%)</td></tr>
                                <tr><td>ECOG PS 2, n (%)</td><td>11 (44.0%)</td><td>66 (15.0%)</td></tr>
                                <tr><td>ECOG PS 3, n (%)</td><td>2 (8.0%)</td><td>0</td></tr>
                                <tr><td>Ann Arbor Stage I or II, n (%)</td><td>1 (4.0%)</td><td>47 (10.7%)</td></tr>
                                <tr><td>Ann Arbor Stage III or IV, n (%)</td><td>24 (96.0%)</td><td>393 (89.3%)</td></tr>
                                <tr><td>IPI Score 2, n (%)</td><td>3 (12.0%)</td><td>167 (38.0%)</td></tr>
                                <tr><td>IPI Score 3-5, n (%)</td><td>22 (88.0%)</td><td>273 (62.0%)</td></tr>
                                <tr><td>Bulky Disease Present, n (%)</td><td>20 (83.3%)</td><td>193 (43.9%)</td></tr>
                                <tr><td>Baseline LDH >ULN, n (%)</td><td>18 (72.0%)</td><td>291 (66.1%)</td></tr>
                                <tr><td>No. of Extranodal Sites ‚â•2, n (%)</td><td>12 (48.0%)</td><td>213 (48.4%)</td></tr>
                                <tr><td>COO - ABC, n (%)</td><td>13 (52.0%)</td><td>102 (30.9%)</td></tr>
                                <tr><td>COO - GCB, n (%)</td><td>11 (44.0%)</td><td>184 (55.8%)</td></tr>
                                <tr><td>DHL (Double Hit Lymphoma), n (%)</td><td>1 (5.5%) of 18 evaluable</td><td>26 (7.9%) of 328 evaluable</td></tr>
                                <tr><td>Mean Ki-67</td><td>83%</td><td>N/A</td></tr>
                            </tbody>
                        </table>
                         <p class="footnote-text mt-1">DHL for KCCC based on N=18 from image; POLARIX DHL from its publication. KCCC cohort had more advanced baseline characteristics.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (KCCC Cohort, N=20 Evaluable)</h2>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">üéØ</div>
                            <div class="infographic-value">75%</div>
                            <div class="infographic-label">EOT PET CRR (vs 78% POLARIX)</div>
                        </div>
                         <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">üìà</div>
                            <div class="infographic-value">88.9%</div>
                            <div class="infographic-label">1-Year PFS</div>
                        </div>
                        <div class="infographic-item teal-theme col-span-1 sm:col-span-2">
                            <div class="infographic-icon icon-teal">‚ù§Ô∏è</div>
                            <div class="infographic-value">94.4%</div>
                            <div class="infographic-label">1-Year OS</div>
                        </div>
                    </div>
                    <p class="text-sm">Despite more unfavorable demographics, response rates, PFS, and OS in the KCCC cohort were comparable to POLARIX trial.</p>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-4 mt-4">
                        <div class="km-plot-container zoomable-image-container">
                            <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PB3294_PFS_KCCC.png" alt="1-Year Progression-Free Survival (KCCC Cohort)" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/E0F2F7/0A2F5C?text=KCCC+PFS+Curve';">
                            <p class="text-xs text-center mt-1">1-Year Progression-Free Survival (KCCC Cohort) (Adapted from Abstract Figure)</p>
                        </div>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PB3294_OS_KCCC.png" alt="1-Year Overall Survival (KCCC Cohort)" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/FFF0E5/0A2F5C?text=KCCC+OS+Curve';">
                            <p class="text-xs text-center mt-1">1-Year Overall Survival (KCCC Cohort) (Adapted from Abstract Figure)</p>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <p class="text-sm">Safety data (adverse events) were not detailed in this abstract, but outcomes were described as comparable to POLARIX.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <p class="text-sm mb-2"><strong>Clinical Implications:</strong></p>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>KCCC experience reinforces the applicability of Pola-R-CHP (Polarix regimen) even in patients with worse prognostic factors.</li>
                <li>Promising results highlight potential effectiveness in real-world settings.</li>
                <li>Data must be interpreted with caution due to small sample size (N=20 evaluable) and need for longer follow-up.</li>
                <li>Further validation needed for similar real-world populations.</li>
                <li>Extended follow-up of KCCC cohort and larger-scale studies in Gulf populations are needed.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>ABC, Activated B-Cell like; ADC, Antibody-Drug Conjugate; AE, Adverse Event; cART, Combined Antiretroviral Therapy; CHEMO, Chemotherapy; CIT, Chemoimmunotherapy; COO, Cell of Origin; CRR, Complete Response Rate; DHL, Double Hit Lymphoma; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EOT, End of Treatment; F/U, Follow-up; GCB, Germinal Center B-cell like; IPI, International Prognostic Index; KCCC, Kuwait Cancer Control Center; LDH, Lactate Dehydrogenase; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; OS, Overall Survival; PET, Positron Emission Tomography; PFS, Progression-Free Survival; Pola, Polatuzumab vedotin; Pola-R-CHP, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory; SoC, Standard of Care; ULN, Upper Limit of Normal.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Hamed RA, Alshemmari S, Hamadah A, et al. Pola-R-CHP in 1st line treatment DLBCL. Kuwait Cancer Center experience. Abstract #PB3294 presented at European Haematology Association (EHA) June 12‚Äì15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3294 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    </body>
</html>
